Literature DB >> 15184872

A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.

Nicolas Jonckheere1, Michaël Perrais, Christophe Mariette, Surinder K Batra, Jean-Pierre Aubert, Pascal Pigny, Isabelle Van Seuningen.   

Abstract

MUC4: encodes a large transmembrane mucin that is overexpressed in pancreatic adenocarcinomas. The molecular mechanisms responsible for that altered pattern of expression are unknown. TGF-beta, a pleiotropic cytokine, regulates numerous genes involved in pancreatic carcinogenesis via activation of the Smads proteins and MUC4 promoter is rich in Smad-binding elements. Our aim was to study whether the regulation of MUC4 expression by TGF-beta in pancreatic cancer cells was strictly dependent on Smad4 activity. Three pancreatic cancer cell lines, CAPAN-1 (MUC4+/Smad4-), CAPAN-2 (MUC4+/Smad4+) and PANC-1 (MUC4-/Smad4+), were used. By RT-PCR, transfection assays and immunohistochemistry, we show that (i) both MUC4 mRNA and apomucin expression are upregulated by TGF-beta, (ii) Smad2 positively cooperates with Smad4 to activate the promoter, (iii) activation of Smad4 by exogenous TGF-beta induces Smad4 binding to the promoter, (iv) Smad7 and c-ski both inhibit activation by Smad4. When Smad4 is mutated and inactive, TGF-beta activates MUC4 expression via MAPK, PI3K and PKA signaling pathways. Absence of expression in PANC-1 cells is due to histone deacetylation. Altogether, these results indicate that upregulation of MUC4 by TGF-beta is restricted to well-differentiated pancreatic cancer cells, and point out a novel mechanism for TGF-beta as a key molecule in targeting MUC4 overexpression in pancreatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15184872     DOI: 10.1038/sj.onc.1207769

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  Structure, evolution, and biology of the MUC4 mucin.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Surinder K Batra
Journal:  FASEB J       Date:  2007-11-16       Impact factor: 5.191

Review 2.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

3.  miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.

Authors:  F Lahdaoui; Y Delpu; A Vincent; F Renaud; M Messager; B Duchêne; E Leteurtre; C Mariette; J Torrisani; N Jonckheere; I Van Seuningen
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

4.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

5.  Smad7 promotes and enhances skeletal muscle differentiation.

Authors:  Helen D Kollias; Robert L S Perry; Tetsuaki Miyake; Arif Aziz; John C McDermott
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

Review 6.  Muc4/MUC4 functions and regulation in cancer.

Authors:  Kermit L Carraway; George Theodoropoulos; Goldi A Kozloski; Coralie A Carothers Carraway
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer.

Authors:  Hua Wang; Xianzhou Song; Craig Logsdon; Guisheng Zhou; Douglas B Evans; James L Abbruzzese; Stanley R Hamilton; Tse-Hua Tan; Huamin Wang
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

8.  4E-BP1 is a target of Smad4 essential for TGFbeta-mediated inhibition of cell proliferation.

Authors:  Rania Azar; Amandine Alard; Christiane Susini; Corinne Bousquet; Stéphane Pyronnet
Journal:  EMBO J       Date:  2009-10-15       Impact factor: 11.598

9.  The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.

Authors:  Valérie Fauquette; Michael Perrais; Sylvain Cerulis; Nicolas Jonckheere; Marie-Paule Ducourouble; Jean-Pierre Aubert; Pascal Pigny; Isabelle Van Seuningen
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

10.  PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.

Authors:  Watcharin Loilome; Sasithorn Yooyuen; Nisana Namwat; Paiboon Sithithaworn; Anucha Puapairoj; Junko Kano; Masayuki Noguchi; Masanao Miwa; Puangrat Yongvanit
Journal:  Tumour Biol       Date:  2012-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.